Tahir Misbah — SEC Form 4 filings
SEC reporting owner CIK 1787359. 12 Form 4 filings on record with FilingPulse; latest filed 2026-03-03.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-03-14 to 2026-03-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 8 legs across 7 filings — 27,797 shares, $118,265 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
- Largest priced transaction: sale of 2,897 shares @ $9.88 ($28,608) in IGM Biosciences, Inc., filed 2024-03-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| IGM Biosciences, Inc. (IGMS) | CHIEF FINANCIAL OFFICER | 10 | — | 8 legs · 27,797 sh · $118,265 | 7 |
| Maze Therapeutics, Inc. (MAZE) | Chief Financial Officer | 2 | — | — | 3 |
Form 4 filings — Tahir Misbah
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-03 | 4 | Maze Therapeutics, Inc. (MAZE) | Grant/award (A): 40,000 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-09-02 | 4 | Maze Therapeutics, Inc. (MAZE) | Grant/award (A): 325,000 (derivative) @ $0 | EDGAR |
| 2025-07-25 | 4 | IGM Biosciences, Inc. (IGMS) | Sale (S): 8,741 @ $1.27 | EDGAR |
| 2025-06-20 | 4 | IGM Biosciences, Inc. (IGMS) | Sale (S): 1,522 @ $1.20 | EDGAR |
| 2025-03-18 | 4 | IGM Biosciences, Inc. (IGMS) | Sale (S): 7,329 @ $1.23 | EDGAR |
| 2024-12-18 | 4 | IGM Biosciences, Inc. (IGMS) | Sale (S): 1,708 @ $7.48 | EDGAR |
| 2024-11-20 | 4 | IGM Biosciences, Inc. (IGMS) | Grant/award (A): 66,667 @ $0 | EDGAR |
| 2024-09-17 | 4 | IGM Biosciences, Inc. (IGMS) | Sale (S): 1,487 @ $11.54 | EDGAR |
| 2024-07-23 | 4 | IGM Biosciences, Inc. (IGMS) | Grant/award (A): 33,111 · Grant/award (A): 2,222 · Disposition to issuer (D): 55,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) | EDGAR |
| 2024-06-18 | 4 | IGM Biosciences, Inc. (IGMS) | Sale (S): 1,570 @ $7.58 | EDGAR |
| 2024-03-15 | 4 | IGM Biosciences, Inc. (IGMS) | Sale (S): 2,897 @ $9.88 · Sale (S): 2,543 @ $10.17 | EDGAR |
| 2024-03-14 | 4 | IGM Biosciences, Inc. (IGMS) | Grant/award (A): 46,250 @ $0 · Grant/award (A): 92,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1787359 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →